Skip to main content
. Author manuscript; available in PMC: 2023 Apr 1.
Published in final edited form as: Circ Heart Fail. 2022 Jan 10;15(4):e008686. doi: 10.1161/CIRCHEARTFAILURE.121.008686

Figure 4. Homeobox a4 (Hoxa4) is a novel target of miR-150 in the heart and HOXA4 is upregulated in patients with heart failure.

Figure 4.

A-C, Real-Time Quantitative Reverse Transcription (QRT)-PCR expression analysis of Hoxa4 (A), flavin-containing dimethylaniline monoxygenase 2 (Fmo2: B) and FAT atypical cadherin 4 (Fat4: C) in left ventricles (LVs) from miR-150 transgenic (TG) and wild type (WT) mice. Data are shown as fold induction of gene expression normalized to glyceraldehyde-3-phosphate dehydrogenase (Gapdh). N=7–8. Unpaired 2-tailed t-test. Note that leucine-rich repeat neuronal 4 (Lrrn4) and MARVEL domain containing 3 (Marveld3) shown in Figure 3G–H are not dysregulated in miR-150 TG mouse LVs. D–F, QRT-PCR expression analysis of HOXA4 (D), FMO2 (E) and LRNN4 (F) in LVs from patients with heart failure with reduced ejection fraction (HFrEF) relative to non-failing heart tissues (N=8–10). Data are shown as fold induction of gene expression normalized to GAPDH. Unpaired 2-tailed t-test. Note that FAT4 shown in Figure 3I is not dysregulated in HFrEF patients and MARVELD3 in Figure 3H is undetectable in human LVs.